Mesoridazine

Mesoridazine

File:Mesoridazine3d.png
Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	oral, intravenous
ATC code	N05AC03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	4%
Metabolism	Hepatic/Renal
Elimination half-life	24 to 48 hours
Excretion	Biliary and renal
Identifiers
IUPAC name 10-{2-[(RS)1-Methylpiperidin-2-yl]ethyl}-2-methylsulfinyl-10H-phenothiazine
CAS Number	5588-33-0
PubChem CID	4078
DrugBank	APRD00610
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H26N2OS2
Molar mass	386.576 g/mol

Mesoridazine besylate (sold as Serentil) is a piperidine antipsychotic neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia, organic brain disorders, psychoneuroses, and alcoholism. It is the besylate salt of a metabolite of thioridazine. Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome. It exerts its actions through blockade of central adrenergic receptors, dopamine receptors, serotonin receptors, and an anticholinergic blocking. It also exerts part of its actions through depression of hypothalamic centers, like other phenothiazines.

Mesoridazine partially derives its name from the prefix "Meso" which means "middle" which is the center of the brain called the limbic system where most dopaminergic activity takes place. The middle of the brain also contains the pineal gland and hypothalamus.

For further information see: Phenothiazine

Mesoridazine was withdrawn from the United States market in 2004.